Klaus Mantwill
Overview
Explore the profile of Klaus Mantwill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mantwill K, Nawroth R
Methods Mol Biol
. 2023 Jul;
2684:155-165.
PMID: 37410233
The application of CRISPR (clustered regularly interspaced short palindromic repeats)-Cas9 technology with pooled guide RNA libraries enables genome-wide screening, which has some advantages over other screening methods using chemical DNA...
2.
Ehrenfeld M, Segeth F, Mantwill K, Brockhaus C, Zhao Y, Ploner C, et al.
J Virol
. 2023 May;
97(6):e0037023.
PMID: 37219458
DNA replication of E1-deleted first-generation adenoviruses (AdV) in cultured cancer cells has been reported repeatedly and it was suggested that certain cellular proteins could functionally compensate for E1A, leading to...
3.
Schober S, Schoening C, Eck J, Middendorf C, Lutsch J, Knoch P, et al.
Clin Cancer Res
. 2023 Mar;
29(10):1996-2011.
PMID: 36892582
Purpose: Ewing sarcoma (EwS) is a highly malignant pediatric tumor characterized by a non-T-cell-inflamed immune-evasive phenotype. When relapsed or metastasized, survival is poor, emphasizing the need for novel treatment strategies....
4.
Kositza J, Nguyen J, Hong T, Mantwill K, Nawroth R
Urol Oncol
. 2023 Feb;
41(5):253.e11-253.e20.
PMID: 36813612
CDK4/6 inhibitors have proven their potency for the treatment of cancer but only in combination with hormone or targeted therapies. The aim of this study was the identification of molecules...
5.
Klawitter M, El-Ayoubi A, Buch J, Ruttinger J, Ehrenfeld M, Lichtenegger E, et al.
Int J Mol Sci
. 2022 Sep;
23(17).
PMID: 36077380
Glioblastoma (GBM) is an obligatory lethal brain tumor with a median survival, even with the best standard of care therapy, of less than 20 months. In light of this fact,...
6.
Koch J, Schober S, Hindupur S, Schoning C, Klein F, Mantwill K, et al.
Nat Commun
. 2022 Aug;
13(1):4689.
PMID: 35948546
CDK4/6 inhibitors (CDK4/6i) and oncolytic viruses are promising therapeutic agents for the treatment of various cancers. As single agents, CDK4/6 inhibitors that are approved for the treatment of breast cancer...
7.
Mantwill K, Klein F, Wang D, Hindupur S, Ehrenfeld M, Holm P, et al.
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34638863
Oncolytic adenovirus therapy is gaining importance as a novel treatment option for the management of various cancers. Different concepts of modification within the adenovirus vector have been identified that define...
8.
Lichtenegger E, Koll F, Haas H, Mantwill K, Janssen K, Laschinger M, et al.
Hum Gene Ther
. 2018 Jun;
30(1):44-56.
PMID: 29916265
Muscle-invasive bladder cancer represents approximately 25% of diagnosed bladder cancer cases and carries a significant risk of death. Oncolytic viruses are novel antitumor agents with the ability to selectively replicate...
9.
Hohl A, Ramms A, Dohmen C, Mantwill K, Bielmeier A, Kolk A, et al.
Hum Gene Ther Methods
. 2017 Aug;
28(5):268-276.
PMID: 28806885
Adenoviral vector production for therapeutic applications is a well-established routine process. However, current methods for measurement of adenovirus particle titers as a quality characteristic require highly purified virus preparations. While...
10.
Mantwill K, Naumann U, Seznec J, Girbinger V, Lage H, Surowiak P, et al.
J Transl Med
. 2013 Sep;
11:216.
PMID: 24044901
Background: The brain cancer stem cell (CSC) model describes a small subset of glioma cells as being responsible for tumor initiation, conferring therapy resistance and tumor recurrence. In brain CSC,...